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Abstract 
Background: Hypermethylation in promoter regions of genes might lead to altered gene func-
tions and result in malignant cellular transformation. Thus, biomarker identification for hyper-
methylated genes would be very useful for early diagnosis, prognosis, and therapeutic treatment of 
oral squamous cell carcinoma (OSCC). The objectives of this study were to screen and validate 
differentially hypermethylated genes in OSCC and correlate the hypermethylation-induced genes 
with demographic, clinocopathological characteristics and survival rate of OSCC.  
Methods: DNA methylation profiling was utilized to screen the differentially hypermethylated 
genes in OSCC. Three selected differentially-hypermethylated genes of p16, DDAH2 and DUSP1 
were further validated for methylation status and protein expression. The correlation between 
demographic, clinicopathological characteristics, and survival rate of OSCC patients with hy-
permethylation of p16, DDAH2 and DUSP1 genes were analysed in the study.  
Results: Methylation profiling demonstrated 33 promoter hypermethylated genes in OSCC. The 
differentially-hypermethylated genes of p16, DDAH2 and DUSP1 revealed positivity of 78%, 80% 
and 88% in methylation-specific polymerase chain reaction and 24% and 22% of immunoreactivity 
in DDAH2 and DUSP1 genes, respectively. Promoter hypermethylation of p16 gene was found 
significantly associated with tumour site of buccal, gum, tongue and lip (P=0.001). In addition, 
DDAH2 methylation level was correlated significantly with patients’ age (P=0.050).  In this study, 
overall five-year survival rate was 38.1% for OSCC patients and was influenced by sex difference. 
Conclusions: The study has identified 33 promoter hypermethylated genes that were significantly 
silenced in OSCC, which might be involved in an important mechanism in oral carcinogenesis. Our 
approaches revealed signature candidates of differentially hypermethylated genes of DDAH2 and 
DUSP1 which can be further developed as potential biomarkers for OSCC as diagnostic, prog-
nostic and therapeutic targets in the future. 
Key words: DNA methylation profiling; promoter hypermethylation; Oral Squamous Cell Carci-
noma; DDAH2; DUSP1; protein expression. 
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Introduction 
Oral cancer is ranked sixth in the world’s list of 
cancer deaths [1] and estimation of 128 000 deaths 
worldwide are due to oral cavity cancer in year of 
2008 by the global burden of cancer (GLOBOCAN) 
[2]. Oral squamous cell carcinoma (OSCC) is the most 
prevalent type of oral cancer in the countries of the 
Association of Southeast Asian Nations (ASEAN) [3].  
Despite the rapid advancement in multimodality 
treatment, the overall 5 years survival rate of OSCC 
has not improved much [2]. In the past decade, the 
cancer treatment modality and patients’ prognostica-
tion depended on conventional assessment in disease 
staging [4].  This is not always an effective treatment 
strategy for halting the progress of OSCC, if the pre-
cise molecular mechanisms involved in regulating 
genetic and epigenetic factors remain unclear. In view 
of epigenetic mechanisms, DNA methylation, in par-
ticular, has provided a better understanding of cancer 
pathogenesis. Thus, novel and promising molecular 
epigenetic biomarkers for OSCC diagnosis and 
prognosis are continuously emerging in this area, 
requiring further evaluation [5, 6]. Therefore, identi-
fication of epigenetic biomarkers that are strongly 
associated with OSCC pathophysiology is urgently 
needed for early diagnostic, detection and prediction 
of progression, and applied molecular-targeted ther-
apies to improve the outcomes of therapeutic treat-
ment.    
The major etiological factors for developing 
OSCC are smoking, alcohol consumption, human 
papilloma virus (HPV) and betel-quid chewing in 
Asian region [7, 8]. How these factors influence DNA 
methylation in oral carcinogenesis have not been well 
studied.  However, smoking has been identified as a 
risk factor associated with hypermethylation of p16, 
RAS association domain family 
(RASSF1A) , RARβ, CDH13, MGMT and GSTP1, ad-
enomatous polyposis coli (APC), and DNA 
methyltransferase 1 which catalyzes methylation 
process in lung cancer  [9, 10]. In addition, the corre-
lations of gene’s hypermethylation with demographic 
and clinicopathological characteristics are known to 
be important for prognosis and cancer risk assessment 
and therapeutic effects of OSCC [11] Thus, we con-
ducted an analysis on the correlation between hy-
permethylation genes with demographic and clini-
copathologic characteristics of OSCC in this study. 
Carcinogenesis is a multistep process, charac-
terized by the accumulation of genetic and/or epige-
netic alterations. Methylation profiling of tumour 
tissues helped to identify the epigenetic alterations, 
especially the ones involving genome-wide hypo-
methylation and gene-specific hypermethylation 
which have now been recognized as important com-
ponents of carcinogenesis [12, 13]. Changes in DNA 
methylation have been reported to occur early in car-
cinogenesis and therefore are potentially important as 
early indicators of cancer. DNA methylation may 
provide an alternate pathway to gene deletion or 
mutation for the loss of tumour suppressor gene 
function [12,14, 15]. Cancer-induced silencing of hy-
permethylation in promoter regions of genes is im-
portant for cancer prevention and therapeutic inter-
ventions as methylated loci are reversible. Thus, 
identification of epigenetic biomarkers of oral cancer 
emerges in improving patients’ survival rate. 
Hypermethylation in tumour suppressor genes 
has been reported in various diseases including can-
cers. The promoter hypermethylation is one of the 
mechanisms leading to gene silencing by either phys-
ically inhibiting the binding of transcription factors, or 
by recruiting proteins that have transcription repres-
sive properties in the cancer pathogenesis [16-18]. 
Thus, this epigenetic process may act as a native to 
genetic alterations involving DNA mutations or 
chromosomal aberrations that disrupt functions of the 
oncogenes or tumour suppressor genes [12,19, 20]. 
Many investigations conducted on cancer-associated 
genes including cyclin-dependent kinase inhibitor 
2A (p16), DAPK1, RARβ, E-CADHERIN, CYCLIN A1, 
p14, p15, p73, RASSF1A, and APC genes, have been 
found to harbor hypermethylated regulatory se-
quences that lead to gene silencing in various cancers 
[5, 6, 16, 18, 21, 22]. However, no gene studied to date 
has been identified as a gene-specific prognostic or 
diagnostic biomarker in oral cancer. Thus, the identi-
fication of biomarkers for early diagnosis or as thera-
peutic target in oral cancer treatment is urgently 
needed. Dual Specificity Phosphatase 1 (DUSP1) and 
Dimethylarginine Dimethylamino hydrolase 
(DDAH2) genes are selected in this study as their 
relevance to OSCC progressions in differential hy-
permethylation of promoter regions are not clearly 
documented [23-25]. 
The recent advances in high throughput tech-
nology like microarray make it possible to generate 
genome-wide quantitative methylation data and 
identify putative candidate genes [26, 27]. In addition, 
various methylation dependent pre-treatments were 
developed to reveal the methylation status of cytosine 
residues, including methylation-specific polymerase 
chain (MS-PCR) technique. MS-PCR that utilizes so-
dium bisulfite treatment of genomic DNA to distin-
guish methylated from unmethylated cytosines, is 
very sensitive to detect one methylated cytosine in 
1000, and the primers used are highly specific and 
cost effective [25, 28].  
In the present study, we screened and identified 
differential promoter hypermethylated genes using 
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methylation microarray analysis, and validated the 
methylation status by MS-PCR and protein expression 
by immunohistochemistry (IHC) assays. Protein ex-
pression of DDAH2 and DUSP1 has been found to be 
reduced in this study; therefore we presume that this 
is the consequence of gene expression silenced by 
promoter hypermethylation. In addition, the correla-
tions of gene’s hypermethylation with demographic 
and clinicopathological characteristics of the study are 
known to be important for cancer prognosis and risk 
assessment [11].  
Materials and Methods  
Samples 
Twenty samples of frozen sections of primary 
oral squamous cell carcinoma comprising  four of 
stage 1, five of stage 2, five of stage 3 and six of stage 
4, and four samples from normal subjects with normal 
oral epithelial surface of reactive epithelial lesions 
were selected for microarray assay. Independent 
samples of archival Formalin-Fixed 
Parafin-Embedded (FFPE) of 4 normal oral mucosa of 
healthy subjects and 40 independent OSCC tissues 
were further selected for differential gene 
hypermethylation status validation using MS-PCR 
and tissue microarray consisting of 40 OSCC tissue 
cores for protein expression by immunohistochemical 
analysis. All the samples were obtained from  the 
Malaysian Oral Cancer Database and Tumour Bank 
System (MOCDTBS) coordinated by Oral Cancer 
Research and Coordinating Center (OCRCC) of 
University of Malaya. Individuals’ consent was 
obtained following appropriate Medical Ethics 
Committee approval of Faculty of Dentistry, 
University of Malaya (Medical Ethical Code no: DF 
OP1101/0049 (L)). No node metastases were 
diagnosed in all OSCC cases. Histopathological 
studies were confirmed by an expert oral pathologist 
to ensure that the samples used for DNA extraction in 
MS-PCR assay and IHC have more than 70% of 
squamous cell carcinomas tissues. All selected 
patients were new cases and had not been previously 
undergone any anticancer therapy. 
DNA extraction of tissues  
Genomic DNA was extracted using the DNEasy 
Blood and Tissue kit (Qiagen, Germany) according to 
the manufacturer’s instructions. The quality and pu-
rity of the extracted DNA was measured using a 
spectrophotometer (Nanodrop; Thermo Fisher Scien-
tific Inc., Wilmington, DE, USA). The DNA purity of 
the samples, measured as 260/280 ratio, had an av-
erage ratio of 1.89 ± 0.18.  
Bisulphite treated DNA 
The protocol was carried out according the 
manufacturer’s instruction (EpiTect, QIAGEN GmbH, 
Hilden, Germany). Briefly, 1 ng - 2 ug of genomic 
DNA was incubated with a sodium bisulfite buffer in 
a thermocycler with alternating cycles of 95°C and 
60°C, through steps of denaturation, sulphonation 
and deamination of cytosine to uracil. The resultant 
DNA was bound again to a membrane and then 
washed and incubated with a desulphonation buffer 
and eluted with 20 µl of elution buffer. The quality 
and purity of the treated DNA was measured using a 
spectrophotometer (Nanodrop Technologies, USA).  
The yields of DNA after bisulphite conversion were in 
the range of 50-100 ng/µl. 
Methylation microarray assay 
Two hundred ng of bisulfite treated DNA was 
applied on the Illumina Infinium HumanMethyla-
tion450 (Illumina Inc. CA, USA) following the manu-
facturer’s protocol. Each point of methylation data 
was presented by fluorescent signals from the meth-
ylated (M) and unmethylated (U) alleles. Methylation 
status of CpG site was measured based on the ratio of 
fluorescent signals from one allele relative to the sum 
of both methylated and unmethylated alleles (β value) 
using Partek Genomic Suite (Partek Inc., St Loius, 
MO, USA) [29].   
Methylation-specific PCR 
The protocol for MS-PCR was performed ac-
cording to the manufacturer’s instructions. Briefly, the 
genomic DNA was converted from unmethylated 
cytosine to uracil by using the Epitect Bisulfite kit 
(Qiagen, Germany) which would not affect the meth-
ylated cytosine. Primers were designed using the 
Methyl Primer Express Software v1.0 (Applied Bio-
systems, USA). Details of the primers for unmethyl-
ated and methylated gene promoter regions are 
shown in Table 1. Unmethylated and methylated 
DNA controls (ZYMO, USA) were used as negative 
and positive controls, respectively. MS-PCR was per-
formed in the Eppendorf Mastercycler Gradient PCR 
(Germany) with the following cycling conditions: Ac-
tivation step: 95oC for 10 min.; 35 cycles of PCR in 
denaturation step: 94oC for 15 sec.; annealing step: Tm 
of primer; extension step: 72oC for 30 sec. and final 
extension: 72oC for 10 min. Five µl of PCR products 
were loaded into 2% agarose gels, electrophoresed 
and visualized using the Image Analyzer (Bio-Rad, 
Hercules, CA), after staining with SYBR Safe DNA gel 
stain.  
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Table 1: MS-PCR primers and conditions 
Genes/ 
Conditions 
P16 DDAH2 DUSP1 
Methylated     
a) Forward primer 5′TTATTAGAGGGTGGGGCGGATCGC3’ 5'TTGGATTACGGTCGTGTC 3' 5'AGTTTGGAAAATTAAAGGAGC 3' 
b) Reverse primer 5′GACCCCGAACCGCGCCGTAA 3′ 5'ACGAAAACTAACCTTCCCG 3' 5'ATACCCACGTTACCTCCATA 3' 
Unmethylated     
a) Forward primer 5′TTATTAGAGGGTGGGGTGGATGT 3′ 5'TTTTTGGATTATGGTTGTGTT 3' 5'GGAGTTTGGAAAATTAAAGGAGT 3' 
b) Reverse primer 5′CAACCCCAAACCACAACCATA A 3′ 5'ATACAAAAACTAACCTTCCCAC 3' 5'CAATACCCACATTACCTCCATA 3 
Annealing 
temperature (oC) 
61 57 58 
Product length (bp) 
 
152 112  119 
UCSC reference 
location 
chr9:21967751-21994490 chr6:31695894-31698245 chr5:172197482-172199606 
 
 
Immunohistochemical staining  
Four micron-thickness of sections were deparaf-
fined, rehydrated and subjected to antigen retrieval 
procedure prior to immunohistochemical (IHC) 
staining. Endogenous peroxidase activity was blocked 
by being incubated with 0.3 % H2O2. The sections 
were incubated with rabbit polyclonal antibodies 
against DDAH2 and DUSP1 (Abcam, USA) proteins. 
These sections were then incubated with biotinylated 
secondary antibody for 30 min. The antigen-antibody 
complexes were visualized using streptavi-
din-horseradish peroxidase conjugate and diamino-
benzidine as chromogen. Negative controls were in-
cluded by omitting the primary antibody. Slides were 
analyzed under a light microscope equipped with a 
digital camera. The IHC labeling was assessed by an 
experienced pathologist using staining scoring pro-
tocol as previously described [30].  All tumoural fields 
were evaluated for staining intensity and adjacent 
normal epithelium served as an internal control. 
Staining intensity was applied rather than counting 
the positively stained cells as methylation does not 
involve whole tissue change. The evaluation was done 
qualitatively by taking the definite positive brown 
staining at the specific cellular location of each pro-
tein. DDAH2 and DUSP1 expressions were associated 
with distinct nuclear and cytoplasmic staining of ep-
ithelial cells. Staining results were examined without 
prior knowledge of the methylation status of MS-PCR. 
P16 gene was not included in this procedure as its 
protein expression has been well studied by many 
other researchers [31, 32]. 
Methylation profiling analysis 
The array signals were uploaded to the Illumi-
na’s Genome Studio software for background nor-
malization and filtered by β values for methylation 
levels using the Illumina’s Genome Studio software 
[33]. Samples which showed fluorescence intensity 
with P<0.001 were included in the study. Methylation 
level was defined as follows: Hypermethylated and 
hypomethylated alleles as those having an average β 
value in that sample of more than 0.4 above or below 
the overall mean for all samples.  Wilcoxon rank sum 
test with p value of 0.001 was corrected with 5% of 
false discovery rate corrections (FDR) for multiple 
testing correction [34]. Multiple testing corrections 
allow a justification of p value based on test numbers 
being performed.  Five percent of FDR are allowed 
having 5% chance of 1 false positive in every 500 
genes. FDR adjust the p value of 0.05 to reflect the 
frequency of false positive in the gene list. Differences 
in average beta values between the two groups are 
presented along with the details of methylation 
probes. Only selected differentially hypermethylated 
probes in OSCC patients passed the filtration criteria 
[35].  
The data was then exported to Partek Genomics 
Suite 6.5 (Partek Inc., USA) where the differentially 
methylated genes between normal subjects and pa-
tients were identified. Unsupervised analysis of hier-
archical clustering was obtained for distribution of 
normal subjects’ and patients’ samples. The list with 
significant methylated genes was generated using 
one-way ANOVA with P < 0.05 and fold change > 2.0 
[27],  which was then subjected to PANTHER (Protein 
ANalysis THrough Evolutionary Relationships) Clas-
sification System (http://www.pantherdb. 
org), to determine their biological pathway that are 
associated with carcinogenesis.  
Data analysis 
The statistical analysis of association between 
patients’ demographic and clinicopathologic charac-
teristics and the selected genes was analyzed using 
Pearson Chi-square, Fisher’s Exact for categorical 
variables and independent T-tests for continuous 
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variables in SPSS software, version 17.0 (SPSS, Chi-
cago, USA). Patients’ demographic data included in 
the data analysis were age, gender, alcohol drinking 
and tobacco smoking and betel quid chewing habits, 
tumour sites, pathological stages, and tumour grad-
ing. Because of the relatively small numbers in each of 
the four grades of pathological stages, we pooled pa-
tients into low stage (stages I and II) or high stage 
(stages III and IV) groups. The correlation of protein 
expression’s strength between DDAH2 and DUSP1 
was considered weak if Pearson’s r was close to 0 and 
strong if close to 1 with significant value of  P < 0.01 
(two-tailed) by using Pearson correlation in SPSS 
software, version 17.0 (SPSS, Chicago, USA). 
Kaplan-Meier and log-rank tests were used to esti-
mate the overall survival for OSCC patients and to 
compare survival curves between demographic, 
clinicopathological data and genes hypermethylation 
for survival rate, respectively. The association was 
considered as statistically significant if P < 0.05. 
Results 
Methylation profiling analysis 
In the Illumina’s Genome Studio software anal-
ysis, one of the 4 normal tissue samples was catego-
rized and filtered as outlier as a quality control for the 
microarray data output, which was then excluded 
from the study. A gene list containing of 33 promot-
er-associated hypermethylated genes was generated 
using average β value of 0.4 in methylation (P < 0.001) 
(Supplementary table 1). Group methylation profiles 
of average beta β value for p16, DDAH2 and DUSP1 
alleles were distinctly differentiated between normal 
and 4 pathological stages (Figs. 1 (a) - 1c)).   
 
 
Fig. 1  Histogram of group methylation profiles of (a) p16 (b) DDAH2 and (c) DUSP1 alleles average β value between normal and 4 pathological stages 
(Stage 1, 2, 3 and 4). Distinct profile shows lower average β value in normal subjects if compared with pathological stage 1, 2, 3 and 4 for (a) p16 (b) DDAH2 
and (c) DUSP1 alleles. 
 
Data obtained from Illumina’s Genome Studio 
software were analyzed by Partek Genomic Suite 
software. A separate heat-map hierarchical clustering 
analysis was performed on normal (N=3) and tumour 
tissues (N=20).  The data set was clustered using 
standard hierarchical method with the Pearson’s cor-
relation to determine the distance function. The clus-
ter set of normal and tumour samples (stage 1, 2, 3 
and 4) clearly segregated the normal from tumour 
samples (Fig. 2). Genes that were differentially hy-
permethylated in their promoter regions between 
tumour and normal samples by at least 2 fold change 
and FDR value <0.05 were further mapped to the 
PANTHER Classification System for pathway analy-
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sis.  The three significant differential genes which 
were selected are p16 (P= 7.94E-02), DDAH2 (P = 
3.72E-01) and DUSP1 (P = 1.669e-7) for microarray 
data validation using MS-PCR and IHC assays. Partek 
Genomic Suite Visualization also demonstrated sig-
nificant enrichment differences in p16, DUSP1 and 
DDAH2 genes for their selected probe regions re-
spectively (P < 0.001) (Figs. 3(a) - 3(c)), which corre-
sponded to the designed primer regions for MS-PCR 
analysis. 
Identification of significant differentially 
methylated genes 
1. p16:  From the Partek Genomics Suite 6.5 
analysis, we found that fold change of p16 
was 2.134 (P=0.000). From the analysis of the 
Illumina’s Genome Studio software, 33% of 
the alleles involved are located within the 
CpG islands, 67% in north shore of islands 
and all are associated with promoter regions. 
2. DDAH2: We decided to further investigate 
its methylation profile because of the ob-
served methylation level enrichment of 2.826 
fold in the study (P=0.000). From the  Illu-
mina’s Genome Studio software analysis, all 
the DDAH2 alleles are found located within 
the CpG islands and 57% are involved in 
promoter regions; suggesting that this gene 
might play a role in oral cancer progression. 
3. DUSP1: We found that the fold change of 
DUSP1 was 2.566 (P=0.000). From the Illu-
mina’s Genome Studio software analysis, the 
DUSP1 alleles are located within the north 
shore of CpG islands and 25% are found in 
promoter regions. Further investigation of 
DUSP1 methylation is needed to clarify its 
role in oral cancer progression. 
Methylation-specific PCR (MS-PCR) 
These 3 selected genes were validated using 
MS-PCR using 4 normal tissues and 40 independent 
OSCC samples. The normal tissues revealed negative 
in methylation levels in p16, DDAH2, and DUSP1 
genes. However in OSCC samples, 78%, 80%, and 88% 
were hypermethylated respectively for p16, DDAH2, 
and DUSP1 in their investigated promoter sites (Fig. 
4), which corresponded with the microarray data. One 
hundred percent (100%) of the tumour revealed hy-
permethylation of the promoter region of at least one 
of the genes analyzed; 42.5% hypermethylation in two 
of the genes analyzed, and 55% hypermethylation in 
all of the three studied genes. There was no significant 
correlation among the hypermethylation status of 
these genes (P > 0.05).  
 
Fig. 2 Heatmap methylation frequency of differentially methylated genes in OSCC. Unsupervised hierarchical clustering was performed on gene meth-
ylation profiles for the normal tissues (N=3) and tumour tissues (N=20, Stage 1, 2, 3 and 4).  The heat map of differentially methylated genes based on 
clustering is shown in the figure.  Each row represents a sample and each column represents a CpG loci. Red colour indicates hypermethylated CpG sites 
and blue colour indicates hypomethylated CpG sites. 
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Fig. 3 Partek Genomic Suite Visualization. The upper panel of each shows the heat map for each probe of (a) p16, (b) DUSP1 and (c) DDAH2 genes in 
normal and four pathological stages. The line graphs in the lower panel of each show log2 ratio of β values of each probe between normal and four 
pathological stages with clear separation (indicated with red arrow). 
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Fig. 4  Three representative agarose gel electrophoretic images of hypermethylation status for genes of (a) p16, (b) DDAH2 and (c) DUSP1 in methylation 
control and tumour samples. DKO represents methylation control; M represents methylated alleles and U represents unmethylated alleles. DKO controls 
(DKO M and DKO U) show bands on each gel and each tumour samples show methylated status of p16 (a), DDAH2 (b), and DUSP1 (c). 
 
 
Fig. 5  Formaline-fixed paraffin-embedded sections of representative Oral Squamous Cell Carcinoma tissues were stained with the antibodies against 
DDAH2 and DUSP1.  (a) Negative immunostaining of DDAH2 in nuclei of the tumour cells. (b) Positive staining of DDAH2 was detected in nuclei of the 
tumour cells. (c) Negative cytoplasmic immunostaining of DUSP1 in the tumour cells. (d) Positive DUSP1 cytoplasmic staining was detected in the tumour 
cells. 
 
Immunohistochemical analysis  
To detect protein expression levels of DUSP1 
and DDAH2, IHC analysis was performed on 4 nor-
mal oral mucosa and 40 OSCC tissues. DDAH2 and 
DUSP1 were nuclear (Fig. 5b) and cytoplasmic (Fig. 
5d) immunoreactivity.  The negative controls revealed 
negative for immunoreactivity of DDAH2 and DUSP1 
and normal mucosa showed positive in DDAH2 and 
DUSP1 immunoreactivity. Immunoreactivity of 
DDAH2 and DUSP1 was demonstrated in 24% and 
22% of tumour tissues, respectively.  The relationship 
between protein expression of DDAH2 and DUSP1 
revealed a strong positive correlation (r = 0.755, P = 
0.001) between these two proteins 
Demographic and clinicopathological charac-
teristics of OSCC  
The demographic and clinicopathologic charac-
teristics of the 40 patients with OSCC are summarized 
in Table 2. These characteristics were age, gender, 
ethnic group, habits of alcohol drinking, tobacco 
smoking and betel-quid chewing, tumour sites, tu-
mour pathological stages, invasive front and tumour 
grading. In survival rate data, there were two missing 
data or lost contact, the follow-up time for 38 patients’ 
OSCC-related death ranged from 2 to 87 weeks, with a 
median follow-up time of 28.5 weeks. The ethnic 
groups of 40 patients consisting of 26 women and 14 
men, with a median age of 59.3 years (age range of 
28–80 years) were Malays (n=5), Chinese (n=6) and 
Indians (n=29). Most of the patients (77.5%) have 
habits of alcohol drinking, tobacco smoking and/or 
betel-quid chewing while only 20% of the patients 
have none of the aforementioned habits. For tumour 
site, 19 (47.5%) were from buccal mucosa, 8 (20%) 
gum, 12 (30%) tongue and 1 (2.5%) lip.  For patholog-
ical stages, one patient (2.5%) had TNM stage 0 dis-
ease, 4 (10%) stage I, 6 (15%) stage II, 3 (7.5%) stage III, 
and 26 (65%) stage IV. For invasive front, four (10%) 
cases each for negative and cohensive front, 29 (72.5%) 
of non cohensive front and 3 (7.5%) of no stated cases. 
In tumour grading, 13 (32.5%) had well differentia-
tion, 25 (62.5%) moderate differentiation and one 
(2.5%) each for poorly and no stated cases.  
There was no statistical significant association 
between the three studied genes with demographic 
and clinicopathologic characteristic of patients’ age, 
gender, ethnicity, habits, tumour sites, pathological 
stages, invasive front and tumour grading (P>.0.05). 
However, a statistically significant association was 
found between p16 gene promoter region with tu-
mour site of buccal, gum, tongue and lip (P=0.001).  In 
addition, DDAH2 hypermethylation was correlated 
significantly with patients’ age (P=0.050).  In this 
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study, the overall survival rate showed 38.1% for 
OSCC patients (95% CI=27.1, 49.1) (Fig. 6) and there 
was a significant difference in the survival rate per-
centage with 24.2% for male and 46.5% for female in 
the sex difference (P=0.050) (Fig.7). However, pa-
tients’ age, ethnicity, habits, tumour sites, tumour 
pathological stages, invasive front and tumour grad-
ing, and hypermethylation of p16, DUSP1 and 
DDAH2 did not influence the survival rate (P>0.05).  
 
Table 2: Demographic and clinicopathological characteristics 
Characteristics  Frequency (Percentage) P value of methylated genes 
    p16 DDAH2 DUSP1 
Gender      
Male 14 (35%)    
Female 26 (66%) 0.546 0.168 0.631 
Ethnic         
Malay 5 (12.5%)     
Chinese 6 (15.0%)     
Indian 29 (72.5.0%) 0.214 0.473 0.560 
         
Age Range  (Years)       
20-39 4 (10%)     
40-59 15 (37.5%)     
60-79 19 (47.5%)     
> 80 2 (5%) 0.196  0.050* 0.574 
          
Habit      
No habit 8 (20%)     
Quit habit 1 (2.5%)     
Alcohol drinking/Tobacco smok-
ing/Betel-quid chewing 
31 (77.5%) 0.855 0.541 0.575 
          
Tumors Site      
Buccal mucosa 19 (47.5%)     
Gum 8(20%)     
Tongue  12 (30%)     
Lip 1 (2.5%)  0.001* 0.700 0.601 
          
Pathological TNM stage      
I 4 (10%)     
II 6 (15%)    
III 4 (10%)    
IV 26 (65%) 0.327 0.587 0.325 
          
Invasive  front  (POI staging)     
Cohensive 6 (15%)    
Non cohensive 31 (77.5%)    
No stated 3 (7.5%) 0.247 0.542 0.278 
          
Differentiation (Tumour grading)     
Well 13 (32.5%)    
Moderate 25 (62.5%)    
Poorly 1 (2.5%)    
No stated 1 (2.5%) 0.862 0.858 0.735 
*Significant difference for promoter hypermethylation in p16 with tumour site by Fisher’s Exact test (P=0.001), and DDAH2 with patients’ age by independent-samples T test 
(P=0.050).   
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Fig. 6 Kaplan-Meier survival curve shows 38.1% of overall five-year sur-
vival rate.  
 
 
Fig. 7 Kaplan-Meier survival curve shows sex difference influences dif-
ferently on OSCC patients’ overall five-year survival rate. 
 
Discussions 
In our study, the methylation profiling demon-
strated clear segregated pattern of the normal from 
tumour samples, which was concordant with those 
reported elsewhere [33, 36, 37]. The microarray-based 
methylation profiling was very specific and useful for 
the identification of signature gene and genes that are 
involved in oral carcinogenesis [38], as the microarray 
reliability has been previously demonstrated and 
validated with single gene assays by Bibikova et al 
[29] and very limited methylation array data available 
in OSCC. To the best of our knowledge, this is the first 
DNA methylation profiling on Malaysian oral cancer 
using the Illumina, Infinium Methylation 450K assay. 
This approach provided comprehensive and high 
throughput data for a genome wide study, which 
covered more than 450,000 methylation loci per sam-
ple at single nucleotide resolution. Further validation 
of candidate genes on a separate cohort of healthy and 
oral cancer population by MS-PCR analysis has al-
lowed us to confirm hypermethylation in promoter 
regions of p16 and DUSP1 as reported by others [39, 
40]. Thus, we confirmed the gene methylation status 
using methylation specific technique. MS-PCR and 
IHC analysis in DUSP1 and DDAH2 genes were reli-
able as the microarray data showed 100% concord-
ance with other studies [41, 42]. Therefore, using 
computational and gene-specific validation ap-
proaches, we were able to identify the potential epi-
genetic biomarkers of oral cancer. 
Tumour suppressor gene, p16 (chromosome 
9p21.3) is a cell cycle regulator involved in the inhibi-
tion of G1 phase progression in normal cells. Howev-
er, promoter hypermethylation of p16 gene in CpG 
islands silences its transcription and represses gene 
expression. In our study, this gene with  promoter 
CpG island hypermethylation  associated with tran-
scriptional silencing, is an early frequent event in 
multiple human cancers including lung, prostate, 
breast and OSCC [14, 43-45]. The inverse correlation 
between the p16 gene hypermethylation and immu-
noreactivity suggests that hypermethylation mecha-
nism is an important event for p16 gene aberration in 
various cancers [31, 32, 46]. 
DDAH2 gene (chromosome 6p21.3) encodes an 
enzyme that is involved in nitric oxide (NO) genera-
tion by regulating cellular concentrations of methyl 
arginine, which in turn inhibits nitric oxide synthase 
(NOS) activity in normal cells [47]. NO is involved in 
vital cell processes of vasodilation, respiration, cell 
migration, immune response and apoptosis. Howev-
er, its dysregulation has been implicated in many 
pathophysiological conditions such as chronic disease 
and cancer [24, 48-51], including the OSCC cases in 
our study.  In this study, DDAH2 gene was found as a 
candidate of hypermethylated gene with 
down-regulation of protein expression in OSCC, 
which seems to play an important role in cancer pro-
gression.  There is a controversy with a recent finding 
reported by Kim et al (2010) showing that the 
up-regulation of DDAH2 gene expression, which is 
involved in the apoptosis inhibitory process, might be 
associated with ovarian carcinoma poor prognosis 
[49].  
The DUSP1 gene (chromosome 5q35.1) encodes 
for the dual specificity protein phosphatase enzyme. It 
acts as an activator in MAPK signaling pathway, to 
dephosphorylate MAP kinase (ERK-2) on both 
'Thr-183' and 'Tyr-185' which are actively involved in 
protein modification, signal transduction and oxida-
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tive stress in normal cells. In addition, DUSP1 is con-
trolled by p53 during cellular response to oxidative 
stress. It is also involved in angiogenesis, invasion and 
metastasis of non-small cell lung cancer [52]. High 
level of DUSP1 promoter hypermethylation was 
demonstrated in our tumour samples as have been 
reported by other cancer researches [39, 52, 53].  
In the study, the normal tissues did not show 
hypermethylation levels; vice-versa in OSCC tissues, 
there are hypermethylated evidences in p16, DDAH2 
and DUSP1 genes. These gene promoters are not 
methylated during the germ line, however, dysregu-
lation of methylation of these gene promoters that 
silences the gene expression causing the cancer pro-
gression [43, 49, 50, 52].  We found no correlation of 
the hypermethylation status among any of the p16, 
DDAH2 and DUSP1 genes. This indicates that the 
hypermethylation of these promoter regions are gene 
specific of OSCC in this study. The association of gene 
hypermethylation with OSCC clinicopathological 
characteristics is essential for better understanding of 
how hypermethylated genes are involved in OSCC 
development.  The findings showed no correlation 
between demographic and clinicopathologi-
cal  characteristics  of OSCC patients'  with the genes’ 
hypermethylation,  except p16, which was statistically 
significant as it was associated with tumour site of 
buccal, gum, tongue, and lip (P = 0.001) and DDAH2 
hypermethylation level was correlated significantly 
with patients’ age (P=0.050).  The overall five-year 
survival rate reported by Uğurluer et al (2006) was 
39% [54], which is very similar to our findings. Our 
study revealed no influence of demographic and 
clinicopathological characteristics, and DUSP1 and 
DDAH2 immunoexpression (p>0.05) except sex dif-
ference (P=0.050) on OSCC patients’ survival rate. A 
large population-based study conducted by Majek et 
al (2013) confirmed a survival advantage of sex dif-
ference on colorectal cancer patients and this is con-
cordant  with the finding of our study [55]. 
Our finding revealed that p16 gene hypermeth-
ylated differentially in various tumour sites of the oral 
cavity. Therefore, cancer cells seem to harbor a het-
erogeneous epigenetic alteration caused by a series of 
clonal expansion of p16 genetic changes in various 
tumour sites of the oral cavity [56]. The studies con-
ducted on different HNSCC tumour sites [13] and 
HPV-driven SCC cases [57] revealed different correl-
ative significant levels of gene hypermethylation. The 
lack of significant correlative association between the 
genes’ promoter hypermethylation with demograph-
ical and clinicopathological characteristics is most 
probably due to the limited number of samples em-
ployed in our study. Therefore, we need a larger 
OSCC sample size for further studies to determine a 
significant hypermethylation status that could be as-
sociated with clinical outcomes.  
Expressions of the gene products were examined 
by immunohistochemistry (IHC).  In the IHC study, 
the inverse correlation of hypermethylation level of 
DDAH2 and DUSP1 and protein expression was evi-
denced in primary OSCC tissues, suggesting that 
protein expression of DDAH2 and DUSP1 was si-
lenced by promoter hypermethylation in OSCC. 
Promoter hypermethylation is an epigenetic change 
which acts as one of the pathways leadings to oral 
carcinogenesis [14]. Similar finding about DUSP1 
hypermethylation in hepatocellular carcinoma has 
been reported by Calvisi et al [53]. However, to the 
best of our knowledge, presently there are no other 
cancer reports about the effect of DDAH2 hyper-
methylation on its protein expression.  In the study, 
the increase of protein expression of the DDAH2 does 
significantly relate to increase of DUSP1, which means 
that both proteins are most likely expressed together 
in the OSCC cases.  
In conclusions, our promoter hypermethylation 
biomarkers screening approach with microarray 
technology and validation by MS-PCR and IHC 
analysis had identified specific candidate genes that 
are DUSP1 and DDAH2 genes for OSCC. Such novel 
biomarkers would be useful for diagnostic, prognostic 
or therapeutic applications. The methylation profiling 
to identify differential promoter hypermethylation 
between OSCC and normal samples may provide a 
tool to decode the molecular understanding in OSCC 
progression.  Our results indicate that protein expres-
sion of DDAH2 and DUSP1 genes were reduced by 
their promoter hypermethylation in OSCC, as pro-
moter hypermethylation is the predominant mecha-
nism in DDAH2 and DUSP1 deregulation. Further 
work will be aimed at elucidating the functional roles 
of DDAH2 and DUSP1 in larger OSCC samples for 
their potential use as hypermethylated-based bi-
omarkers. 
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